{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:09:06Z","timestamp":1791263346809,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1016\/j.leukres.2008.11.023","type":"journal-article","created":{"date-parts":[[2009,1,8]],"date-time":"2009-01-08T05:40:00Z","timestamp":1231393200000},"page":"686-692","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Compound 48, a novel dual PPAR \u03b1\/\u03b3 ligand, inhibits the growth of human CML cell lines and enhances the anticancer-effects of imatinib"],"prefix":"10.1016","volume":"33","author":[{"given":"Janina","family":"Bertz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanbing","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies","family":"W\u00e4chter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Possinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Phillip Koeffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Elstner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2008.11.023_bib1","first-page":"169","article-title":"Chronic myelogenous leukemia: update on biology and treatment","volume":"13","author":"Faderl","year":"1999","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.leukres.2008.11.023_bib2","first-page":"85","article-title":"Chromosome studies on normal and leukemic human leukocytes","volume":"25","author":"Nowell","year":"1960","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.leukres.2008.11.023_bib3","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1056\/NEJM198810133191506","article-title":"The molecular genetics of Philadelphia chromosome-positive leukemias","volume":"319","author":"Kurzrock","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2008.11.023_bib4","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1161\/01.CIR.98.19.2088","article-title":"Mechanism of action of fibrates on lipid and lipoprotein metabolism","volume":"98","author":"Staels","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.leukres.2008.11.023_bib5","first-page":"1175","article-title":"Expression of peroxisome proliferator-activated receptor alpha, and PPARalpha regulated genes in spontaneously developed hepatocellular carcinomas in fatty acyl-CoA oxidase null mice","volume":"21","author":"Meyer","year":"2002","journal-title":"Int J Oncol"},{"key":"10.1016\/j.leukres.2008.11.023_bib6","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1194\/jlr.M200072-JLR200","article-title":"Apoptosis induced by clofibrate in Yoshida AH-130 hepatoma cells: role of HMG-CoA reductase","volume":"44","author":"Canuto","year":"2003","journal-title":"J Lipid Res"},{"key":"10.1016\/j.leukres.2008.11.023_bib7","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0300-483X(03)00055-6","article-title":"Mechanisms involved in growth inhibition induced by clofibrate in hepatoma cells","volume":"187","author":"Muzio","year":"2003","journal-title":"Toxicology"},{"key":"10.1016\/j.leukres.2008.11.023_bib8","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1006\/taap.2002.9538","article-title":"Cytotoxic effect of peroxisome proliferator fenofibrate on human HepG2 hepatoma cell line and relevant mechanisms","volume":"185","author":"Jiao","year":"2002","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.leukres.2008.11.023_bib9","first-page":"126","article-title":"Peroxisome proliferator-activated receptors (PPAR) agonists affect cell viability, apoptosis and expression of cell cycle related proteins in cell lines of glial brain tumors","volume":"52","author":"Strakova","year":"2005","journal-title":"Neoplasma"},{"key":"10.1016\/j.leukres.2008.11.023_bib10","doi-asserted-by":"crossref","first-page":"R546","DOI":"10.1186\/bcr913","article-title":"A retinoid X receptor (RXR)-selective retinoid reveals that RXR-alpha is potentially a therapeutic target in breast cancer cell lines, and that it potentiates antiproliferative and apoptotic responses to peroxisome proliferator-activated receptor ligands","volume":"6","author":"Crowe","year":"2004","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.leukres.2008.11.023_bib11","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/sj.cdd.4400551","article-title":"Bezafibrate as differentiating factor of human myeloid leukemia cells","volume":"6","author":"Scatena","year":"1999","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.leukres.2008.11.023_bib12","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/S0171-9335(98)80109-X","article-title":"Enhanced differentiation of HL-60 leukemia cells to macrophages induced by ciprofibrate","volume":"77","author":"Bronfman","year":"1998","journal-title":"Eur J Cell Biol"},{"key":"10.1016\/j.leukres.2008.11.023_bib13","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2337\/diabetes.47.4.507","article-title":"PPAR-gamma: adipogenic regulator and thiazolidinedione receptor","volume":"47","author":"Spiegelman","year":"1998","journal-title":"Diabetes"},{"key":"10.1016\/j.leukres.2008.11.023_bib14","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/0959-437X(95)80025-5","article-title":"Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor gamma","volume":"5","author":"Tontonoz","year":"1995","journal-title":"Curr Opin Genet Dev"},{"key":"10.1016\/j.leukres.2008.11.023_bib15","doi-asserted-by":"crossref","first-page":"8806","DOI":"10.1073\/pnas.95.15.8806","article-title":"Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice","volume":"95","author":"Elstner","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.leukres.2008.11.023_bib16","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1023\/A:1016114026769","article-title":"Novel therapeutic approach: ligands for PPARgamma and retinoid receptors induce apoptosis in bcl-2-positive human breast cancer cells","volume":"74","author":"Elstner","year":"2002","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.leukres.2008.11.023_bib17","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1023\/B:NEON.0000003728.80052.a8","article-title":"Ligands for PPARgamma and RAR cause induction of growth inhibition and apoptosis in human glioblastomas","volume":"65","author":"Zang","year":"2003","journal-title":"J Neurooncol"},{"key":"10.1016\/j.leukres.2008.11.023_bib18","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1097\/00001813-200411000-00004","article-title":"Ligands of peroxisome proliferator-activated receptor gamma induce apoptosis in multiple myeloma","volume":"15","author":"Eucker","year":"2004","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.leukres.2008.11.023_bib19","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.leukres.2003.07.005","article-title":"Peroxisome proliferator-activated receptor gamma ligands induce growth inhibition and apoptosis of human B lymphocytic leukemia","volume":"28","author":"Zang","year":"2004","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2008.11.023_bib20","doi-asserted-by":"crossref","first-page":"904041","DOI":"10.1155\/2008\/904041","article-title":"Rosiglitazone Inhibits Adrenocortical Cancer Cell Proliferation by Interfering with the IGF-IR Intracellular Signaling","volume":"2008","author":"Giulia","year":"2008","journal-title":"PPAR Res"},{"key":"10.1016\/j.leukres.2008.11.023_bib21","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1158\/1535-7163.MCT-05-0347","article-title":"Rosiglitazone suppresses human lung carcinoma cell growth through PPARgamma-dependent and PPARgamma-independent signal pathways","volume":"5","author":"Han","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.leukres.2008.11.023_bib22","first-page":"1477","article-title":"Induction of apoptosis in colorectal cancer cells by peroxisome proliferators-activated receptor gamma activation up-regulating PTEN and inhibiting PI3K activity","volume":"118","author":"Chen","year":"2005","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.leukres.2008.11.023_bib23","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S1074-7613(04)00030-5","article-title":"Transcriptional inactivation of STAT3 by PPARgamma suppresses IL-6-responsive multiple myeloma cells","volume":"20","author":"Wang","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.leukres.2008.11.023_bib24","doi-asserted-by":"crossref","first-page":"671","DOI":"10.2174\/156800906779010227","article-title":"The JAK-STAT pathway: a therapeutic target in hematological malignancies","volume":"6","author":"Ferrajoli","year":"2006","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.leukres.2008.11.023_bib25","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1016\/S0960-894X(03)00505-5","article-title":"5-Aryl thiazolidine-2,4-diones: discovery of PPAR dual alpha\/gamma agonists as antidiabetic agents","volume":"13","author":"Desai","year":"2003","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.leukres.2008.11.023_bib26","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1021\/jm030621d","article-title":"(2R)-2-ethylchromane-2-carboxylic acids: discovery of novel PPARalpha\/gamma dual agonists as antihyperglycemic and hypolipidemic agents","volume":"47","author":"Koyama","year":"2004","journal-title":"J Med Chem"},{"key":"10.1016\/j.leukres.2008.11.023_bib27","first-page":"1312","article-title":"A novel PPAR alpha\/gamma dual agonist inhibits cell growth and induces apoptosis in human glioblastoma T98G cells","volume":"25","author":"Liu","year":"2004","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.leukres.2008.11.023_bib28","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.1182\/blood-2005-05-2103","article-title":"Growth inhibition and apoptosis in human Philadelphia chromosome-positive lymphoblastic leukemia cell lines by treatment with the dual PPARalpha\/gamma ligand TZD18","volume":"107","author":"Liu","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.11.023_bib29","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.4161\/cc.5.19.3259","article-title":"Dual PPARalpha\/gamma ligand TZD18 either alone or in combination with imatinib inhibits proliferation and induces apoptosis of human CML cell lines","volume":"5","author":"Zang","year":"2006","journal-title":"Cell Cycle"},{"key":"10.1016\/j.leukres.2008.11.023_bib30","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/sj.leu.2403241","article-title":"JAK\/STAT, Raf\/MEK\/ERK, PI3K\/Akt and BCR-ABL in cell cycle progression and leukemogenesis","volume":"18","author":"Steelman","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2008.11.023_bib31","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nrc1567","article-title":"Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia","volume":"5","author":"Ren","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.leukres.2008.11.023_bib32","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.bcp.2005.02.021","article-title":"Relative importance of apoptosis and cell cycle blockage in the synergistic effect of combined R115777 and imatinib treatment in BCR\/ABL-positive cell lines","volume":"69","author":"Miyoshi","year":"2005","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.leukres.2008.11.023_bib33","first-page":"7149","article-title":"Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571)","volume":"62","author":"La Rosee","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2008.11.023_bib34","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv Enzyme Regul"},{"key":"10.1016\/j.leukres.2008.11.023_bib35","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.leukres.2008.11.023_bib36","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.leukres.2008.11.023_bib37","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1172\/JCI30890","article-title":"Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency","volume":"117","author":"Shah","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.leukres.2008.11.023_bib38","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1182\/blood.V84.6.1731.1731","article-title":"Tyrosine phosphorylation of CRKL in Philadelphia+ leukemia","volume":"84","author":"ten Hoeve","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.11.023_bib39","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1182\/blood-2007-09-114454","article-title":"Potentiation of antileukemic therapies by the dual PI3K\/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells","volume":"111","author":"Weisberg","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.11.023_bib40","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1158\/1535-7163.MCT-06-0446","article-title":"Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells","volume":"6","author":"Nam","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.leukres.2008.11.023_bib41","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00277-006-0098-0","article-title":"Antiproliferative effect of indomethacin on CML cells is related to the suppression of STATs\/Bcl-XL signal pathway","volume":"85","author":"Zhang","year":"2006","journal-title":"Ann Hematol"},{"key":"10.1016\/j.leukres.2008.11.023_bib42","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S1079-9796(03)00070-6","article-title":"Involvement of Akt kinase in the action of STI571 on chronic myelogenous leukemia cells","volume":"31","author":"Kawauchi","year":"2003","journal-title":"Blood Cells Mol Dis"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212608005250?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212608005250?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:56:40Z","timestamp":1758934600000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212608005250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["S0145212608005250"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2008.11.023","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2009,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Compound 48, a novel dual PPAR \u03b1\/\u03b3 ligand, inhibits the growth of human CML cell lines and enhances the anticancer-effects of imatinib","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2008.11.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Ltd. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}